The alternative: Dimetindene maleate as a tranquilizer and anxiolytic

2025 · doi:10.22541/au.168494126.65953250/v2
preprint OA: closed
Full text JSON View at publisher
⚙ AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text ⓘ

This preprint report examines the pharmacological properties and proposed therapeutic potential of dimetindene maleate, describing it as an antihistamine with additional sedative effects and discussing its mechanism of action, pharmacokinetics, clinical applications, potential side effects, and future research directions for anxiety disorders. The authors frame dimetindene maleate as a medium-strong tranquilizer and anxiolytic and provide a broad narrative overview rather than presenting specific new experimental results in the text provided. A major stated caveat is that it is a preprint and not peer reviewed, with the abstract noting that peer review status may not be updated correctly in the repository. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In the meantime, this work has undergone peer review under the auspices of Swabian Research. In some instances, however, the repository in which it is deposited has not implemented this important change in status, and this note is therefore being provided for clarification. This report examines the pharmacological properties and therapeutic potential of Dimetindene maleate as a medium strong tranquilizer and anxiolytic. Dimetindene maleate is an antihistamine with additional sedative effects, making it suitable for managing anxiety and promoting relaxation. This report delves into the mechanism of action, pharmacokinetics, clinical applications, and potential side effects of Dimetindene maleate, providing a comprehensive understanding of its therapeutic benefits and limitations. Additionally, this report explores current research trends and future prospects for Dimetindene maleate as a promising option in the management of anxiety disorders.
Full text 1,980 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

In the meantime, this work has undergone peer review under the auspices of Swabian Research. In some instances, however, the repository in which it is deposited has not implemented this important change in status, and this note is therefore being provided for clarification. This report examines the pharmacological properties and therapeutic potential of Dimetindene maleate as a medium strong tranquilizer and anxiolytic. Dimetindene maleate is an antihistamine with additional sedative effects, making it suitable for managing anxiety and promoting relaxation. This report delves into the mechanism of action, pharmacokinetics, clinical applications, and potential side effects of Dimetindene maleate, providing a comprehensive understanding of its therapeutic benefits and limitations. Additionally, this report explores current research trends and future prospects for Dimetindene maleate as a promising option in the management of anxiety disorders. Supplementary Material File (dimetindene maleate as an anxiolytic.pdf) - Download - 203.14 KB Information & Authors Information Copyright This work is licensed under a Non Exclusive No Reuse License.

Keywords

Authors Metrics & Citations Metrics Article Usage 929views 180downloads Citations Download citation Helmut Kaucher, Sven Stoltenberg, Marius Lazar, et al. The alternative: Dimetindene maleate as a tranquilizer and anxiolytic. Authorea. 21 November 2025. DOI: https://doi.org/10.22541/au.168494126.65953250/v2 DOI: https://doi.org/10.22541/au.168494126.65953250/v2 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00